Braveheart Bio IPO: offering terms from its S-1
Braveheart Bio priced its IPO at $18 a share on 6 Aug 2026 and raised $383 million. Its shares trade on Nasdaq as BRVE.
Headlines
- Net loss, 2025
- $66M
- IPO price
- $18
- $383M raised
Braveheart Bio IPO terms
From the final prospectus (424B4).
- Exchange
- The Nasdaq Global Market
- Ticker
- BRVE
- IPO price
- $18
- Shares offered
- 21,250,000
- Raised
- $383M
- Registered
- $367M, the amount the filing fee is paid on
- Underwriters
- Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel and Cantor
- First filed
- 15 Jul 2026
Braveheart Bio revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2025 | - | -$67M | -$66M |
| First quarter of 2026 | - | -$15M | -$14M |
Braveheart Bio share structure and company facts
- Employees
- 30
- Headquarters
- San Francisco, CA
Braveheart Bio shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $18
- Priced 6 Aug 2026
- First close
- $29.80
- +66% on the IPO price
- Latest close
- $21.87
- +22% on the IPO price
Braveheart Bio's IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Braveheart Bio's newest prospectus (S-1/A filed 30 Jul 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.